Search

MannKind Corp

Fermé

SecteurSoins de santé

3.51 2.93

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.51

Max

3.54

Chiffres clés

By Trading Economics

Revenu

5.7M

13M

Ventes

1.6M

78M

P/E

Moyenne du Secteur

39.2

34.393

Marge bénéficiaire

16.793

Employés

403

EBITDA

8.3M

27M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+163.92% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-316M

1.2B

Ouverture précédente

0.58

Clôture précédente

3.51

Sentiment de l'Actualité

By Acuity

14%

86%

21 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

MannKind Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 août 2025, 21:43 UTC

Résultats

Constellation Software 2Q Revenue Rises, Profit Shrinks

8 août 2025, 16:39 UTC

Acquisitions, Fusions, Rachats

Vinci Faces Reduced Earnout Payments to ACS for Cobra IS Deal

8 août 2025, 22:42 UTC

Acquisitions, Fusions, Rachats

The Paramount Merger Was a Bad Deal for Old Shareholders. Buying the Stock Is a Good Bet for New Ones. -- Barrons.com

8 août 2025, 21:31 UTC

Market Talk
Résultats

Cautious Long-Term Outlook For Natural Diamond Prices -- Market Talk

8 août 2025, 21:00 UTC

Résultats

Constellation Software 2Q Rev $2.84B >CSU.T

8 août 2025, 21:00 UTC

Résultats

Constellation Software 2Q Net $56M >CSU.T

8 août 2025, 21:00 UTC

Résultats

Constellation Software 2Q EPS $2.66 >CSU.T

8 août 2025, 20:55 UTC

Market Talk

Ahead of Cisco's Earnings, Investors Should Expect Conservatism -- Market Talk

8 août 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

8 août 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 août 2025, 20:35 UTC

Market Talk

Mexico's Industrial Production Seen Higher in June -- Market Talk

8 août 2025, 20:28 UTC

Résultats

MP Materials Stock Soars Even Higher on Earnings. The Future Looks Bright, Too. -- Barrons.com

8 août 2025, 20:28 UTC

Résultats

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 août 2025, 20:20 UTC

Acquisitions, Fusions, Rachats

Boeing's Spirit AeroSystems Deal Gets U.K. Approval. It's Part of the Turnaround. -- Barrons.com

8 août 2025, 20:08 UTC

Résultats

Tredegar: Recent Decline in Orders, Which Is a Measure of Future Sales Volume, Is Due to Lower Demand for Aluminum Extrusions in U.S. and Customers Pausing Orders to Evaluate New Higher Tariff >TG

8 août 2025, 19:34 UTC

Market Talk

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 août 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Futures Settle Under $3 -- Market Talk

8 août 2025, 19:13 UTC

Market Talk

Oil Futures End Volatile Week Lower -- Market Talk

8 août 2025, 18:21 UTC

Market Talk

Gold Gains for the Week as Tariffs Go Forward -- Market Talk

8 août 2025, 17:27 UTC

Résultats

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 août 2025, 17:09 UTC

Résultats

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 août 2025, 17:03 UTC

Résultats

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 août 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

8 août 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 août 2025, 15:53 UTC

Acquisitions, Fusions, Rachats

Vinci: New Provisions Will Have No Significant Impact on Vinci's Financial Statements

8 août 2025, 15:51 UTC

Acquisitions, Fusions, Rachats

Vinci, ACS Terminate Agreement Regarding Creation of Joint Venture in Renewable Energy

8 août 2025, 15:50 UTC

Acquisitions, Fusions, Rachats

Vinci to Pay EUR300M of That Sum to ACS Taking Into Account Payments Already Made

8 août 2025, 15:48 UTC

Acquisitions, Fusions, Rachats

Vinci, ACS Agreed to Fix Earn-Out Related to Cobra IS Developments in Renewable Energy at EUR380M Payable in Cash

8 août 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Vinci: Acquisition of Cobra IS Was Completed Dec. 31, 2021

8 août 2025, 15:46 UTC

Acquisitions, Fusions, Rachats

Vinci: Agreement Will Definitively Settle Certain Provisions Related to Acquisition of Cobra IS

Comparaison

Variation de prix

MannKind Corp prévision

Objectif de Prix

By TipRanks

163.92% hausse

Prévisions sur 12 Mois

Moyen 9.29 USD  163.92%

Haut 12 USD

Bas 7 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

7

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

4.079 / 4.323Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

21 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.